Sunday, April 29, 2018, 1 – 2:30pm

Retinal microglia in degenerative diseases: Why function matters
Speakers: Heping Xu, Florian Sennlaub, Daniel Saban

This SIG will present novel animal models, molecular analysis tools and functional measures to characterize the pro-active role of microglia in influencing the outcome of retinal degenerative diseases including AMD and rare photoreceptor dystrophies.

A Matter of Life or Death: Regulation of RGC Survival by Glia and Interneurons
Speakers: Adriana Di Polo, Jeffrey Goldberg, Wei Lei, Paul Rosenberg

We will discuss recent evidence indicating that retinal astrocytes/Mueller cells, microglia, and interneurons govern the survival of retinal ganglion cells after traumatic or ischemic optic nerve injury and in glaucoma.

Update on clinical gene therapy trials for inherited retinal diseases
Speakers: Isabelle Audo, Mark Pennesi, Robert MacLaren, Stephen Russell

In this SIG, updates on current inherited retinal dystrophy gene therapy trials will be discussed by a panel of clinical investigators actively involved in these trials. Points of interest involving pros/cons of foveal detachment will be discussed.

Extracellular Vesicles and the Anterior Segment
Speakers: Brian McKay, Yutao Liu, Dimitri Azar, James Zieske

Extracellular Vesicles (EVs) are recognized as a source of cell communication. In the anterior segment, it is believed that can be used for therapy. SIG will focus on recent progress about EVs in the context of pathophysiology, diagnosis and treatment.

Towards Guidelines for Mouse Electroretinography (ERG)
Speakers: Mathias Seeliger, Machelle Pardue, Laura Frishman, Neal Peachey, Suresh Viswanathan

ERG is essential in the functional evaluation of disease models and as preclinical biomarker in therapeutic trials. However, there are to date no guidelines for this technique. This SIG is intended as a kick-off meeting to start the process.

Biomarkers and Surrogate Endpoints in Ophthalmic Clinical Research
Speakers: Edoardo Villani, Penny Asbell, Felipe Medeiros, Alastair Denniston, Stela Vujosevic

This SIG, follow-up of the 2017 IOVS Special Issue, will critically discuss the use of biomarkers and surrogate endpoints in ophthalmic Clinical Trials, focusing on scientific advances, validation processes, regulatory issues, and related challenges.

Delivery of therapeutics to ocular tissues
Speakers: Rajiv Mohan, Terete Borras, Mark Prausnitz, Justin Hanes, Thomas Fuchsluger

This SIG discusses novel and translational applications to deliver therapeutics to ocular tissues presenting various tools and ways of drug delivery. A broad range of application areas (ocular surface, cornea, glaucoma and retina) will be covered.

Monday, April 30, 2018, 1:30 – 3pm

Telemedicine and Artificial Intelligence using Deep Learning Systems to Screen and Monitor Diabetic Retinopathy, Glaucoma and Age-related Macular Degeneration using Different Imaging Modalities
Speakers: Daniel Ting, Louis Pasquale, Phillippe Burlina, Aaron Lee, Robert Chang, Gavin Tan, Rohit Varma, Leopold Schmetterer, Mingguang He, Jennifer Sun, Tin Aung

This SIG will focus on the design, implementation and potential pitfalls of tele-medicine programs and deep learning systems for 3 major eye conditions - diabetic retinopathy (DR), glaucoma and age-related macular degeneration (AMD) on multi-modal imaging.

Phagocytic mechanisms in ocular tissues: from physiological to pathological processes
Speakers: Paul McMenamin, Derek Royer, Florian Sennlaub

Phagocytic processes are part of the normal eye homeostasis. However, phagocytosis is also linked to pathological developments. This SIG will highlight the importance of maintaining a functional equilibrium from the cornea to the RPE/choroid.

Omega-3 Fatty Acid Supplementation for Dry Eye Disease: Data on Efficacy and Safety from the Dry Eye Assessment and Management (DREAM©) Study
Speakers: Penny Asbell, Reza Dana, Meng Lin

Results of the Dry Eye Assessment and Management (DREAM<sup>©</sup>) Study, an NEI-sponsored clinical trial of omega-3 supplementation for moderate to severe dry eye disease, will be available in April 2018. Data on efficacy and their interpretation will be discussed.

Managing Patients with Diabetic Macular Edema, Diabetic Retinopathy, Neovascular and Non-Neovascular AMD, and Retinal Vein Occlusion: How to Best Utilize the Latest Data from Clinical Trials
Speakers: David Boyer, Judy Kim, Robert Avery

The SIG will provide a forum for interpretation of significance of data and discussion on how results will be applied to clinical practice. There will be no rehash of data presented elsewhere at ARVO. Strong audience participation will be encouraged.

Eye and Brain - the interrelationship and pathology
Speakers: Neeru Gupta, Stuart Graham, Alfredo Sadun

There is increasing evidence supporting the link between eye and brain diseases. The panel will discuss the phenomenon of bidirectional neurodegeneration in the visual pathway and the potential use of ocular findings as biomarkers for brain pathology.

Membrane dynamics in RPE health and disease
Speakers: Kapli Bharti, David Williams, Catherine Bowes Rickman

The SIG will focus on membrane trafficking in the RPE in relation to retinal physiology and pathology. Panelists will discuss mechanisms that regulate the maintenance of apical processes and tight junctions in the RPE, and how impaired membrane dynamics can impact phagosome degradation, intracellular complement activation, and formation of sub-RPE deposits.

The Lasker/IRRF Initiative for Innovation in Vision Science: Glaucoma and Diabetic Retinopathy
Speakers: Leonard Levin, Claude Burgoyne, David Calkins, M Francesca Cordeiro, Timothy Kern, Lloyd Aiello

The Lasker/IRRF Initiative for Innovation in Vision Science aims to accelerate understanding and treatments of diseases of the retina and visual system. This SIG will highlight programs on glaucoma and diabetic retinopathy.

Tuesday, May 1, 2018, 1:30 – 3pm

Objective Quantification of Intraocular Inflammation: Using Newer Technologies to Overcome an Old Challenge
Speakers: Sunil Srivastava, Alastair Denniston, Rupesh Agrawal, Aniruddha Agarwal

To objectively grade intraocular inflammation is a complex task of utmost importance both in the everyday practice and in clinical trials. The panel will discuss the topic and the potential use of new technologies to overcome the present limitations.

Next-Gen autofluorescence imaging - let's get ready
Speakers: Theodore Smith, Neel Dey, Martin Hammer, Thomas Ach, Kevin Schey

Fundus autofluorescence, a metabolic marker for RPE health, informs diagnosis and management of outer retinal disease especially AMD. New data from clinical imaging and human eye pathology prompt new ideas about old and new fluorophores in AMD.

Immune tolerance in steady state and ocular surface/corneal diseases
Speakers: Shigeto Shummura, Jerry Niederkorn, Stephen Pflugfelder

The ocular surface is exposed to irritants, allergens, and pathogens, thus immune tolerance is crucial for maintaining a clear, non-inflamed state. This SIG is focused on mechanisms of tolerance induction and disruption in the context of eye disease.

Molecular Imaging of the Retina in Health and Disease
Speakers: Mahnaz Shahidi, Jesse Schallek, Grazyna Palczewska, Yoshihiko Katayama, Nora Denk

This session will focus on recent advances toward cellular and molecular imaging of the retina in health and disease, with emphasis on development and translation of optical imaging instrumentation and targeted imaging contrast agents.

Optical Coherence Tomography Angiography of the Eye
Speakers: James Fujimoto, Stephen Burns, Linda Zangwill

OCT angiography is a rapidly developing technology to non-invasively image and measure retinal, choroidal, and optic nerve blood flow. This forum discusses technological approaches, disease applications, and clinical interpretation.

Gene therapy of glaucoma
Speakers: Val Sheffield, Zhijian Wu, Markus Kuehn, Ting Xie

With the advent of efficient genome editing tools, crispr-cas9 for example, it is reasonable to target glaucoma-causing genes for therapeutic purpose. Our SIG meeting will focus on the current development and feasibility in glaucoma gene therapy.

Lipid and Lipid Targeted Therapies for Eye Diseases- past, present and future
Speakers: Nicolas Bazan, Paul Bernstein, Igor Butovich, Robert Anderson

Lipid molecules have been identified as novel therapies, therapeutic targets, nutraceuticals and disease biomarkers. This SIG will gather a panel of world experts of lipids and discuss the past present and future of lipid science in eye diseases.

The Lasker/IRRF Initiative for Innovation in Vision Science: Restoring Vision to the Blind and Amblyopia
Speakers: Botond Roska, Eberhart Zrenner, Jane Snowden

The Lasker/IRRF Initiative for Innovation in Vision Science aims to accelerate understanding and treatments of diseases of the retina and visual system. This SIG will highlight programs on restoring vision to the blind and amblyopia.

Wednesday, May 2, 2018, 1:30 – 3pm

Animal Models of Ocular Trauma
Speakers: Brittany Coats, Machelle Purdue, Chloe Naomi Thomas

Retinal and optic nerve pathologies from models of non-accidental-, blunt-, and blast-induced injury will be presented and compared. We will discuss animal models, injury mechanisms, and molecular pathways that could lead to therapies.

Biobanking with a Purpose: Advancing Research in Ophthalmology
Speakers: Rebecca Parrish, Sarah Coupland, Brenda Gallie, Robert Hufnagel, Liliana Guedez

A discussion to develop consensus and methods to enhance the utility, best practices and regulatory considerations of biobanks in clinical, translational, diagnostic and basic vision research.

Regenerative Medicine Wnt Signaling and Retinal vascular Disease
Speakers: Kimberly Drenser, Eric Nudleman, Lois Smith

We will present and discuss the role of Wnt signaling in the management of Pediatric and Adult retinal vascular disease. How Wnt signaling might be used therapeutically to repair or regenerate retinal capillaries damaged by acquired or inherited disease.

Optical Coherence Tomography and Ophthalmic Surgery: New Visualizations, Functional Analysis, and Enabling Robotic Assistance
Speakers: William Dupps, David Huang, Cynthia Toth, Jin Kang, Joseph Izatt

Panel discussion of advances in intraoperative OCT. A panel of leading intraoperative OCT technologists and clinicians will discuss advances in intra-operative OCT and the future of ophthalmic surgery.

Patient report outcome measures (PROMs) in clinical glaucoma research: refining current tools, exploring new opportunities and improving means of data capture and analysis
Speakers: Pradeep Ramulu, Ecosse Lamoureux, Eva Fenwick

A discussion of: - Current problems and inconsistencies in clinical glaucoma PROMs - Strategies for improved PROM choice and data analysis (eg item response theory) - Future PROM development and implementation - New opportunities for data collection

Ontology and Common Data Elements for Collaborative Research in Ophthalmology
Speakers: Liz Amos, Kerry Goetz, Helene Dollfus, Flora Lum, Peter Robinson

This SIG will provide Ontologies, Controlled Vocabularies and Clinical Data Capture best practices. Attendees will learn how to evaluate research needs to decide the level of detail needed for hypothesis testing and select the data capture model.

Phagocytosis in the outflow pathway: what we can learn from other ocular tissues
Speakers: Emeline Nandrot, Nicholas Marsh-Armstrong, Florian Sennlaub

This SIG will bring together experts in phagocytosis in different ocular tissues to identify and discuss how phagocytic activity in the trabecular meshwork might regulate outflow pathway tissue function and contribute to glaucoma disease.

Mechanisms and therapies for corneal endothelial dysfunction
Speakers: Thomas Fuchsluger, Ula Jurkunas, Albert Jun, Jodhbir Mehta, Shigeru Kinoshita

Corneal endothelial disfunction is a major causes for lamellar and penetrating keratoplasties around the globe. This SIG discusses pathologies and novel translational treatment concepts for corneal endothelial disfunction. This includes cell and gene therapy approaches, novel surgical techniques and cell injection therapies.